CombinatoRx Receives Huntington's Disease Society Leadership Award

Main Category: Huntingtons Disease
Article Date: 24 Oct 2007 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that it has received the Marjorie Guthrie Leadership Award from the Huntington's Disease Society of America (HDSA) during their 40th Anniversary Guthrie Awards Dinner in New York City to benefit the Woody and Marjorie Guthrie Research fund. Alexis Borisy, President and CEO of CombinatoRx was present to accept the award.

The Guthrie Family created the Woody and Marjorie Guthrie Research fund to pay tribute to the legendary folk singer Woody Guthrie, who died from complications associated with Huntington's disease (HD), and to his widow, Marjorie, who founded the HDSA 40 years ago and worked tirelessly to convince Congress to begin research in the area of HD, and other neurological diseases.

"The quest to find answers that will relieve the symptoms and eventually the cause of HD requires new approaches, new methodologies, and new ways of thinking. As this year's recipient of the Marjorie Guthrie Leadership Award, CombinatoRx exemplifies these qualities with its unique approach to drug discovery as well as continued patient support efforts," commented C. Walt Johnston, Chairman of the Huntington's Disease Society of America Board of Trustees.

"We are proud to be affiliated with the Huntington's Disease Society of America and are honored to be recognized for our efforts as we work together to improve the lives of those affected by Huntington's disease," commented Alexis Borisy, President and Chief Executive Officer of CombinatoRx.

In August 2005, CombinatoRx, Inc. entered into a research agreement with CHDI, Inc. part of a foundation aimed at preventing and treating Huntington's disease to perform joint research and development to discover novel therapeutics for the treatment of Huntington's disease.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive Phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts.

http://www.combinatorx.com.

About Huntington's Disease Society of America

The Huntington's Disease Society of America (HDSA) is a national non-profit voluntary health agency dedicated to finding a cure for Huntington's Disease (HD). HDSA provides vital support, information and educational services to improve the lives of those affected by HD, offer resources and guidance for HD families through our national network of volunteer-based chapters and affiliates as well as through the HDSA Centers of Excellence for Family Services and promote and support research to find a cure for HD.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its research efforts relating to Huntington's disease, its research agreement with CHDI, Inc., its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx its Huntington's disease research, involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology as applied to Huntington's disease, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2007 CombinatoRx, Incorporated. All rights reserved.

http://www.combinatorx.com